drugset / Trial / NCT02206035

A Study of Tacrolimus/Methotrexate and Tocilizumab to Prevent Acute Graft-Versus-Host Disease (AGVD) After Allogeneic Hematopoietic Stem Cell Transplant

NCT02206035 ↗

Phase 2 Completed 45 enrolled William R. Drobyski, MD
NaSingle-groupOpen-labelPrevention

Summary

This is a phase II open label trial designed to evaluate the efficacy of Tac/MTX/Toc in preventing graft versus host disease (GVHD). Outcomes of patients on this clinical trial will be compared to those of contemporary controls from the CIBMTR.

Timeline

Start
2014-12
Primary completion
2018-09
Completion
2018-09

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Methotrexate Small molecule 10 mg/m2 —
Subject Tacrolimus Small molecule — —
Subject Tocilizumab Monoclonal antibody 8 mg/kg Intravenous